ReviewCureus2026
Internet Sales of "Research Grade Compounds": The Opioid SR-17018 (SR-17) as an Example.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several internet sites promote the sale of "research grade compounds." Although the purchaser attests that they are over 18 years of age, they know that the substances have not been approved by regulatory agencies and promise that they will not use them for human consumption, the compounds are supplied in tablet form, which is inconvenient for research use but very convenient for human consumption. One such compound is the opioid SR-17018 (aka "SR-17"). SR-17018 was originally synthesized at Scripps Research as part of a discovery effort to test whether a G-protein-'biased' mu-opioid receptor (MOR) agonist could separate the undesirable opioid effect of respiratory depression from the desirable effect of analgesia. It never progressed through the stages necessary for human clinical trials, so it remained a research "tool" drug. Regardless of the initial intent, the United States Drug Enforcement Agency (DEA) alerts that some "research grade compounds" such as SR-17018 are emerging as recreational or abused substances. If so, the absence of adequate human data creates a problem for healthcare providers who may encounter an overdose of such a compound without an adequate evidence base upon which to draw. This narrative review presents SR-17018 as a case study of the clinical uncertainty that a "research grade compound" introduces. It synthesizes in vitro, ex vivo, and plausible human pharmacology of SR-17018, and it presents an emergency department physician's experience with a suspected SR-17 overdose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.